Examination of treatment responses with mycophenolate mofetil in Black vs White patients with systemic sclerosis

OBJECTIVE: Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this differential disease severity. METHODS: Self-identified Black and White patients with scleroderma who had MMF exposure were selected from the Johns Hopkins Scleroderma Center Research Registry. We used linear mixed effects models to study the trajectory of forced vital capacity % predicted (pFVC) and modified Rodnan skin scores (mRSS) during follow-up. RESULTS: Among 662 patients with measured baseline pFVC, the average (SD) baseline pFVC was 64.3 (15.6) for Black patients and 86.9 (18.6) for White patients (p<0.001). During follow-up, the estimated annual change ±SE in pFVC among Black patients was -0.53±0.46 pre-MMF and -0.58±0.27 post-treatment (pre-post difference of -0.04±0.54 (p=0.939)). Among White patients, estimated annual changes in pFVC pre- and post-MMF were -1.20± 0.23 and -0.56±0.13, with a pre-post difference of +0.64±0.27 (p=0.019). Among 452 patients with diffuse scleroderma, the baseline mRSS was 17.2 (SD 10.1) for Black patients and 21.4 (SD 11.1) for White patients (p<0.001). The estimated difference in annual change in mRSS post-MMF treatment compared to pre-treatment was -0.87±0.32 for Black patients, compared to -0.68±0.16 among White patients (p=0.598). CONCLUSION: Black patients have more severe pulmonary disease at presentation. While Black and White patients have similar rates of change in pFVC and mRSS after MMF exposure, Black patients did not have a meaningful difference in pFVC change post-MMF compared to pre-MMF, suggesting further study is needed in this population.

Authors

Institutions

Publication Details

Journal
Arthritis Care & Research
Published
2026-11-16
DOI
https://doi.org/10.1002/acr.80207
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Examination of treatment responses with mycophenolate mofetil in Black vs White patients with systemic sclerosis

Scott L. Zeger, Laura Kathleen Hummers, Adrianne Woods, Ji Soo Kim et al.
Arthritis Care & Research
Systemic Sclerosis and Related Diseases
article

Examination of treatment responses with mycophenolate mofetil in Black vs White patients with systemic sclerosis

Scott L. Zeger, Laura Kathleen Hummers, Adrianne Woods, Ji Soo Kim, Fredrick M. Wigley, Jamie Perin, Lauren N. Smith, Ami A Shah
article en

Abstract

OBJECTIVE: Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this differential disease severity. METHODS: Self-identified Black and White patients with scleroderma who had MMF exposure were selected from the Johns Hopkins Scleroderma Center Research Registry. We used linear mixed effects models to study the trajectory of forced vital capacity % predicted (pFVC) and modified Rodnan skin scores (mRSS) during follow-up. RESULTS: Among 662 patients with measured baseline pFVC, the average (SD) baseline pFVC was 64.3 (15.6) for Black patients and 86.9 (18.6) for White patients (p<0.001). During follow-up, the estimated annual change ±SE in pFVC among Black patients was -0.53±0.46 pre-MMF and -0.58±0.27 post-treatment (pre-post difference of -0.04±0.54 (p=0.939)). Among White patients, estimated annual changes in pFVC pre- and post-MMF were -1.20± 0.23 and -0.56±0.13, with a pre-post difference of +0.64±0.27 (p=0.019). Among 452 patients with diffuse scleroderma, the baseline mRSS was 17.2 (SD 10.1) for Black patients and 21.4 (SD 11.1) for White patients (p<0.001). The estimated difference in annual change in mRSS post-MMF treatment compared to pre-treatment was -0.87±0.32 for Black patients, compared to -0.68±0.16 among White patients (p=0.598). CONCLUSION: Black patients have more severe pulmonary disease at presentation. While Black and White patients have similar rates of change in pFVC and mRSS after MMF exposure, Black patients did not have a meaningful difference in pFVC change post-MMF compared to pre-MMF, suggesting further study is needed in this population.

Arthritis Care & Research
Johns Hopkins University (US), Georgetown University Medical Center (US)
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon